ACM
CRNX icon

Aster Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Aster Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-158
Closed -$7.36K – 939
2025
Q4 		$7.36K Buy
+158
New +$7.03K ﹤0.01% 805
2025
Q3 		– Sell
-260
Closed -$7.48K – 1042
2025
Q2 		$7.48K Buy
+260
New +$8.03K ﹤0.01% 823

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Aster Capital Management's CRNX Position: Q1 2026 in Review

Aster Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 158 shares — an estimated $7.36K sold.

Aster Capital Management first reported a position in CRNX in Q2 2025 and held it in 2 quarters. The position peaked at $7.48K in Q2 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Aster Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 158 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $7.36K.
  • Aster Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Aster Capital Management's Crinetics Pharmaceuticals position peaked at $7.48K in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.